HYALASE

This brand name is authorized in Hong Kong SAR China, Israel, Malta, New Zealand, Singapore.

Active ingredients

The drug HYALASE contains one active pharmaceutical ingredient (API):

1	Hyaluronidase ovine UNII 64R4OHP8T0 - HYALURONIDASE (OVINE)
	Hyaluronidase is an enzyme that has a temporary and reversible depolymerising effect on the polysaccharide hyaluronic acid, which is present in the intercellular matrix of connective tissue.
	Read more about Hyaluronidase

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
HYALASE Powder for solution for injection/infusion	MPI, EU: SmPC	Medicines & Healthcare Products Regulatory Agency (GB)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
B06AA03	Hyaluronidase	B Blood and blood forming organs → B06 Other hematological agents → B06A Other hematological agents → B06AA Enzymes
Discover more medicines within B06AA03

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
HK	Department of Health Drug Office	35245
IL	מִשְׂרַד הַבְּרִיאוּת	8615
MT	Medicines Authority	MA143/07201
NZ	Medicines and Medical Devices Safety Authority	2784
SG	Health Sciences Authority	10302P